PT  - JOURNAL ARTICLE
AU  - Roach, Paul J.
AU  - Francis, Roslyn
AU  - Emmett, Louise
AU  - Hsiao, Edward
AU  - Kneebone, Andrew
AU  - Hruby, George
AU  - Eade, Thomas
AU  - Nguyen, Quoc A.
AU  - Thompson, Benjamin D.
AU  - Cusick, Thomas
AU  - McCarthy, Michael
AU  - Tang, Colin
AU  - Ho, Bao
AU  - Stricker, Philip D.
AU  - Scott, Andrew M.
TI  - The Impact of <sup>68</sup>Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study
AID  - 10.2967/jnumed.117.197160
DP  - 2018 Jan 01
TA  - Journal of Nuclear Medicine
PG  - 82--88
VI  - 59
IP  - 1
4099  - http://jnm.snmjournals.org/content/59/1/82.short
4100  - http://jnm.snmjournals.org/content/59/1/82.full
SO  - J Nucl Med2018 Jan 01; 59
AB  - 68Ga-PSMA PET/CT scanning has been shown to be more sensitive than conventional imaging techniques in patients with prostate cancer. This prospective Australian multicenter study assessed whether 68Ga-PSMA PET/CT imaging affects management intent in patients with primary or recurrent prostate cancer. Methods: Before undertaking 68Ga-PSMA PET imaging, referring medical specialists completed a questionnaire detailing relevant demographic and clinical data as well as their proposed management plan. A separate follow-up questionnaire was completed after the 68Ga-PSMA PET/CT scan results were available to determine whether the management plan would change. Results: A total of 431 patients with prostate cancer from 4 Australian centers had pre– and post–68Ga-PSMA management plans completed. Scans were obtained for primary staging of intermediate- and high-risk disease in 25% of patients and for restaging/biochemical recurrence in 75% of patients. Overall, 68Ga-PSMA PET/CT scanning led to a change in planned management in 51% of patients. The impact was greater in the group of patients with biochemical failure after definitive surgery or radiation treatment (62% change in management intent) than in patients undergoing primary staging (21% change). Imaging with 68Ga-PSMA PET/CT revealed unsuspected disease in the prostate bed in 27% of patients, locoregional lymph nodes in 39%, and distant metastatic disease in 16%. Conclusion: 68Ga-PSMA PET/CT scans detect previously unsuspected disease and may influence planned clinical management in a high proportion of patients with prostate cancer. The impact was greater in patients with biochemical recurrence. These results demonstrate the potential clinical value of 68Ga-PSMA PET/CT in management of prostate cancer.